作者
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie SL Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam Brufsky, Kevin Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
发表日期
2023/5
期刊
JCO Precision Oncology
卷号
7
页码范围
e2200532
出版商
Wolters Kluwer Health
简介
PURPOSE
For patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i). After disease progression, which often comes with ESR1 resistance mutations (ESR1-MUT), which therapies to use next and for which patients are open questions. An active area of exploration is treatment with further CDK4/6i, particularly abemaciclib, which has distinct pharmacokinetic and pharmacodynamic properties compared with the other approved CDK4/6 inhibitors, palbociclib and ribociclib. We investigated a gene panel to prognosticate abemaciclib susceptibility in patients with ESR1-MUT MBC after palbociclib progression.
METHODS
We examined a multicenter retrospective cohort of patients with ESR1-MUT MBC who received abemaciclib after …
学术搜索中的文章
JO Brett, TD Dubash, GN Johnson, A Niemierko… - JCO Precision Oncology, 2023